Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Treatment of R/R CLL: Efficacy and Safety of Ibrutinib, PFS Benefit With VenR, LOXO-305 Is Highly Effective in Heavily Pretreated B-cell Malignancies & CAR T-cell Therapy is a Promising Alternative
Login to view comments.
Click here to Login
